The journal Therapeutics and Clinical Risk Management published a study showing that Actemra offers an enhanced probability of being the best treatment for inducing an ACR20 response versus placebo, methotrexate (MTX), Humira or Enbrel. The study, which compared available data on the efficacy of biologic agents indicated for monotherapy treatment, found that Actemra allows a significantly greater proportion of patients with rheumatoid arthritis to attain clinical benefit within 6 months compared to other biologic therapies.
"The results of this analysis reinforce Actemra as an effective biologic monotherapy for the treatment of rheumatoid arthritis," said Christine Birchwood, Medical Science Director, Genentech Immunology.
